Authors: Alexandra Thompson
Alzheimer’s disease (AD) is the most commonly diagnosed form of dementia, involving the parts of the brain that control thought, memory and language. As a neurodegenerative disease, it begins with mild memory loss and leads to loss of the ability to carry on a conversation and respond to the environment. With no known cure, an increasing prevalence and an aging population, there is a clear and urgent need for an effective treatment.
In a poster presentation at the 2015 International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden, a team of researchers from the University of Michigan (MI, USA) presented data on a stem cell therapy they have been developing for AD, using a Neuralstem (MD, USA) cell line.
The team presented data demonstrating the effects of HK532-IGF-1 cell transplantation into the peri-hippocampus of a mouse model of AD. HK532-IGF-1 is a proprietary line of cortical neural stem cells genetically modified to express IGF-1, known to have a wide range of neuroprotective effects.
These mice showed better hippocampal-dependent behavioral and had lower b-amyloid plaque levels compared with untreated mice, indicating a positive impact on learning and memory, as well as AD pathology. The researchers hope to continue their investigations into the benefits of HK532-IGF-1 transplantation.
Sources: McGinley LM, Kashlan ON, Chen KS et al. Human neural stem cells expressing IGF-1: a novel cellular therapy for Alzheimer’s disease. Presented at: International Society for Stem Cell Research (ISSCR) Annual Meeting, Stockholm, Sweden (25 June 2015); Neuralstem press release
Originally posted on RegMedNet